CR20120623A - Composiciones Farmacéuticas que comprenden Monohidrato de Lactato de 4-amino-5-Fluoro-3-[6-(4-Metil-Piperazin-1-Il)-1H- Bencimidazol-2-Il]-1H-Quinolin-2-Ona - Google Patents
Composiciones Farmacéuticas que comprenden Monohidrato de Lactato de 4-amino-5-Fluoro-3-[6-(4-Metil-Piperazin-1-Il)-1H- Bencimidazol-2-Il]-1H-Quinolin-2-OnaInfo
- Publication number
- CR20120623A CR20120623A CR20120623A CR20120623A CR20120623A CR 20120623 A CR20120623 A CR 20120623A CR 20120623 A CR20120623 A CR 20120623A CR 20120623 A CR20120623 A CR 20120623A CR 20120623 A CR20120623 A CR 20120623A
- Authority
- CR
- Costa Rica
- Prior art keywords
- benzimidazol
- quinolin
- piperazin
- fluoro
- amino
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- AEEGSXBXXSNVIR-UHFFFAOYSA-N O.OC(C(=O)O)C.N1C(C=CC2=CC=CC=C12)=O Chemical compound O.OC(C(=O)O)C.N1C(C=CC2=CC=CC=C12)=O AEEGSXBXXSNVIR-UHFFFAOYSA-N 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una composición farmacéutica para su administración oral, la cual comprende monohidrato de monolactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1H-bencimidazol-2-il]-1H-quinolin-2-ona,un relleno en una cantidad del 15 al 70 por ciento en peso, un desintegrante en una cantidad de menos del 15 por ciento en peso, un derrapante y/o un lubricante en una cantidad del 0.1 al 10 por ciento en peso, en donde las cantidades en peso se basan en el peso total de la composición.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10168028 | 2010-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20120623A true CR20120623A (es) | 2013-02-11 |
Family
ID=42751565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20120623A CR20120623A (es) | 2010-06-30 | 2012-12-11 | Composiciones Farmacéuticas que comprenden Monohidrato de Lactato de 4-amino-5-Fluoro-3-[6-(4-Metil-Piperazin-1-Il)-1H- Bencimidazol-2-Il]-1H-Quinolin-2-Ona |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US9545402B2 (es) |
| EP (2) | EP3446686A1 (es) |
| JP (1) | JP6043281B2 (es) |
| KR (2) | KR101840182B1 (es) |
| CN (2) | CN103068373A (es) |
| AR (1) | AR081776A1 (es) |
| AU (1) | AU2011273519B2 (es) |
| BR (1) | BR112012033479A8 (es) |
| CA (1) | CA2801826C (es) |
| CL (1) | CL2012003729A1 (es) |
| CO (1) | CO6650354A2 (es) |
| CR (1) | CR20120623A (es) |
| CU (1) | CU20120177A7 (es) |
| DK (1) | DK2588086T3 (es) |
| DO (1) | DOP2012000324A (es) |
| EA (1) | EA026244B1 (es) |
| EC (1) | ECSP13012411A (es) |
| ES (1) | ES2701161T3 (es) |
| GE (1) | GEP20146049B (es) |
| GT (1) | GT201200348A (es) |
| HU (1) | HUE042355T2 (es) |
| IL (1) | IL223799A (es) |
| MA (1) | MA34387B1 (es) |
| MX (1) | MX345404B (es) |
| MY (2) | MY163369A (es) |
| NI (1) | NI201200189A (es) |
| NZ (1) | NZ604055A (es) |
| PE (1) | PE20130481A1 (es) |
| PL (1) | PL2588086T3 (es) |
| PT (1) | PT2588086T (es) |
| SG (1) | SG186182A1 (es) |
| TN (1) | TN2012000574A1 (es) |
| TR (1) | TR201818761T4 (es) |
| TW (1) | TWI583384B (es) |
| UA (1) | UA109659C2 (es) |
| UY (1) | UY33472A (es) |
| WO (1) | WO2012001074A2 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013063003A1 (en) | 2011-10-28 | 2013-05-02 | Novartis Ag | Method of treating gastrointestinal stromal tumors |
| EP2809312A1 (en) | 2012-01-31 | 2014-12-10 | Novartis AG | Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer |
| MX2015000457A (es) | 2012-07-11 | 2015-04-08 | Novartis Ag | Metodo de tratamiento de tumores del estroma gastrointestinal. |
| US9395468B2 (en) | 2012-08-27 | 2016-07-19 | Ocular Dynamics, Llc | Contact lens with a hydrophilic layer |
| WO2014058785A1 (en) | 2012-10-10 | 2014-04-17 | Novartis Ag | Combination therapy |
| CN109125283A (zh) | 2013-03-14 | 2019-01-04 | 艾慕恩治疗公司 | 用于口服脱敏的花生制剂的制备 |
| US9492535B2 (en) | 2013-03-14 | 2016-11-15 | Aimmune Therapeutics, Inc. | Peanut formulations and uses thereof |
| AU2014348502B2 (en) | 2013-11-15 | 2019-08-15 | Tangible Science, Inc. | Contact lens with a hydrophilic layer |
| US20150343075A1 (en) * | 2014-06-02 | 2015-12-03 | Aimmune Therapeutics | Placebo formulations and uses thereof |
| CA2970010A1 (en) | 2014-12-09 | 2016-06-16 | Karen Havenstrite | Medical device coating with a biocompatible layer |
| TWI829098B (zh) | 2015-01-02 | 2024-01-11 | 美商梅拉洛伊卡公司 | 細菌組成物 |
| AU2018358125A1 (en) | 2017-11-02 | 2020-05-14 | Societe Des Produits Nestle S.A. | Methods of oral immunotherapy |
| JP2022532547A (ja) | 2019-05-10 | 2022-07-15 | アイミューン セラピューティクス，インコーポレイテッド | ピーナツアレルギー患者の生活の質を改善するための方法 |
| US10835531B1 (en) | 2019-06-18 | 2020-11-17 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
| WO2022026851A1 (en) * | 2020-07-31 | 2022-02-03 | The Scripps Research Institute | Targeted rna degradation allows precision repurposing of protein-targeted small molecule medicines to rna |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5009897A (en) * | 1988-06-24 | 1991-04-23 | Abbott Laboratories | Pharmaceutical granules and tablets made therefrom |
| AU9327501A (en) | 2000-09-11 | 2002-03-26 | Chiron Corp | Quinolinone derivatives |
| CA2496164C (en) | 2002-08-23 | 2010-11-09 | Chiron Corporation | Benzimidazole quinolinones and uses thereof |
| US20060172006A1 (en) * | 2003-10-10 | 2006-08-03 | Vincent Lenaerts | Sustained-release tramadol formulations with 24-hour clinical efficacy |
| GB0504203D0 (en) * | 2005-03-01 | 2005-04-06 | Novartis Ag | Organic compounds |
| CN102070614B (zh) * | 2005-05-23 | 2014-01-15 | 诺华股份有限公司 | 4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮乳酸盐的结晶和其它形式 |
| EA200800360A1 (ru) * | 2005-07-22 | 2008-06-30 | Мириад Дженетикс, Инк. | Формуляции с высоким содержанием лекарства и дозированные формы |
| MY148529A (en) * | 2005-11-29 | 2013-04-30 | Novartis Ag | Formulations of quinolinones |
| CN101316593B (zh) * | 2005-11-29 | 2012-05-02 | 诺瓦提斯公司 | 喹啉酮类的制剂 |
| RU2009136669A (ru) | 2007-03-09 | 2011-04-20 | Новартис АГ (CH) | Лечение меланомы |
| PL2205244T3 (pl) | 2007-11-08 | 2014-01-31 | Ambit Biosciences Corp | Sposoby podawania N-(5-tert-butylo-izoksazol-3-ilo)-N’-{4-[7-(2-morfolin-4-ylo-etoksy)-imidazo-[2,1-b]-[1,3]-benzotiazol-2-ilo]-fenylo} mocznika do leczenia chorób proliferacyjnych |
| PE20091628A1 (es) * | 2008-03-19 | 2009-11-19 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona |
| EP2108365A1 (en) * | 2008-04-09 | 2009-10-14 | LEK Pharmaceuticals d.d. | Single dosage pharmaceutical formulation comprising eprosartan mesylate |
| MA34106B1 (fr) | 2010-04-16 | 2013-03-05 | Novartis Ag | Combinaison de composés organiques |
-
2011
- 2011-06-28 AR ARP110102271A patent/AR081776A1/es unknown
- 2011-06-28 UY UY0001033472A patent/UY33472A/es not_active Application Discontinuation
- 2011-06-29 KR KR1020177035178A patent/KR101840182B1/ko active IP Right Grant
- 2011-06-29 TR TR2018/18761T patent/TR201818761T4/tr unknown
- 2011-06-29 KR KR1020137002390A patent/KR20130091319A/ko not_active Application Discontinuation
- 2011-06-29 EP EP18193864.8A patent/EP3446686A1/en active Pending
- 2011-06-29 PL PL11734043T patent/PL2588086T3/pl unknown
- 2011-06-29 BR BR112012033479A patent/BR112012033479A8/pt not_active Application Discontinuation
- 2011-06-29 PE PE2012002517A patent/PE20130481A1/es not_active Application Discontinuation
- 2011-06-29 EA EA201291410A patent/EA026244B1/ru not_active IP Right Cessation
- 2011-06-29 DK DK11734043.0T patent/DK2588086T3/en active
- 2011-06-29 NZ NZ604055A patent/NZ604055A/en not_active IP Right Cessation
- 2011-06-29 MY MYPI2012005339A patent/MY163369A/en unknown
- 2011-06-29 UA UAA201213966A patent/UA109659C2/uk unknown
- 2011-06-29 TW TW100122927A patent/TWI583384B/zh not_active IP Right Cessation
- 2011-06-29 US US13/703,120 patent/US9545402B2/en active Active
- 2011-06-29 CA CA2801826A patent/CA2801826C/en active Active
- 2011-06-29 EP EP11734043.0A patent/EP2588086B1/en active Active
- 2011-06-29 PT PT11734043T patent/PT2588086T/pt unknown
- 2011-06-29 CN CN2011800320095A patent/CN103068373A/zh active Pending
- 2011-06-29 MX MX2012015091A patent/MX345404B/es active IP Right Grant
- 2011-06-29 JP JP2013517282A patent/JP6043281B2/ja active Active
- 2011-06-29 HU HUE11734043A patent/HUE042355T2/hu unknown
- 2011-06-29 WO PCT/EP2011/060949 patent/WO2012001074A2/en active Application Filing
- 2011-06-29 AU AU2011273519A patent/AU2011273519B2/en active Active
- 2011-06-29 SG SG2012089413A patent/SG186182A1/en unknown
- 2011-06-29 GE GEAP201112986A patent/GEP20146049B/en unknown
- 2011-06-29 CN CN201710208616.1A patent/CN106943355B/zh active Active
- 2011-06-29 MA MA35575A patent/MA34387B1/fr unknown
- 2011-06-29 ES ES11734043T patent/ES2701161T3/es active Active
- 2011-11-29 MY MYPI2016002052A patent/MY177741A/en unknown
-
2012
- 2012-12-05 TN TNP2012000574A patent/TN2012000574A1/en unknown
- 2012-12-11 CR CR20120623A patent/CR20120623A/es unknown
- 2012-12-20 NI NI201200189A patent/NI201200189A/es unknown
- 2012-12-20 IL IL223799A patent/IL223799A/en active IP Right Grant
- 2012-12-21 DO DO2012000324A patent/DOP2012000324A/es unknown
- 2012-12-21 GT GT201200348A patent/GT201200348A/es unknown
- 2012-12-24 CU CU2012000177A patent/CU20120177A7/es unknown
- 2012-12-27 CO CO12234898A patent/CO6650354A2/es not_active Application Discontinuation
- 2012-12-28 CL CL2012003729A patent/CL2012003729A1/es unknown
-
2013
- 2013-01-30 EC ECSP13012411 patent/ECSP13012411A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20120623A (es) | Composiciones Farmacéuticas que comprenden Monohidrato de Lactato de 4-amino-5-Fluoro-3-[6-(4-Metil-Piperazin-1-Il)-1H- Bencimidazol-2-Il]-1H-Quinolin-2-Ona | |
| GT201000182A (es) | Regimen de dosificacion asociado con ésteres de paliperidona inyectables de acción prolongada | |
| AR078159A1 (es) | Composicion que contiene palmitoil-etanolamida ultra-micronizada .metodo. compuesto.forma polimorfica. | |
| UY32923A (es) | Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico | |
| GT201400111A (es) | Triazolopiridinas sustituidas | |
| HN2011003011A (es) | Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas | |
| UY32926A (es) | Compuestos como antagonistas de los receptores de ácido lisofosfatídico | |
| AR081681A1 (es) | METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA | |
| BR112015011430A2 (pt) | composição para liberação imediata e prolongada | |
| ECSP15004752A (es) | Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles | |
| CU20120171A7 (es) | Triazolopiridinas sustituidas | |
| CR20130239A (es) | Compuestos de triazolopiridina | |
| BR112012024673A2 (pt) | composição anestésica termogelificante | |
| CO6741223A2 (es) | Derivados de azetidina útiles para el tratamiento de enfermedades metabólicas e inflamatorias | |
| PE20120791A1 (es) | Composiciones y metodos para terapia prolongada con aminopiridinas | |
| CL2016001094A1 (es) | Silicato de zirconio microporoso para el tratamiento de hipercalemia. | |
| CL2012003341A1 (es) | Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades. | |
| NZ711847A (en) | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof | |
| CO6450623A2 (es) | Parasiticidas sanguineos | |
| BR112015012220A2 (pt) | composição simbiótica e uso da mesma | |
| BR112014015193A8 (pt) | composição enriquecida com glicoproteína como um aditivo para alimento e/ou ração e/ou como um agente terapêutico | |
| UA97076C2 (ru) | Мазь противовоспалительная на основе сульфаниламида | |
| CU20130141A7 (es) | Triazolopiridinas |